- Home
- Companies
- north america
- lung cancer
Show results for
Refine by
Lung Cancer Suppliers In North America
72 companies found
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian ...
based inDoylestown, PENNSYLVANIA (USA)
Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality. Our proprietary ...
based inSyracuse, NEW YORK (USA)
Mesothelioma is an aggressive cancer that affects the lining of the lungs, heart, or abdomen. Caused by the inhalation of asbestos fibers, mesothelioma is often diagnosed in older individuals who worked with asbestos products. Prognosis for ...
There is no cure for mesothelioma, but clinical trials and experimental treatments offer hope for the future. In the never-ending effort to eradicate cancer, there are medical and scientific researchers constantly looking for new ways to attack this ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, ...
based inCambridge, MASSACHUSETTS (USA)
Alphageneron Pharmaceuticals is a clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer cells (NK) cell and antibody-based therapies to treat cancer. Our seasoned team of biopharmaceutical executives, ...
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK ...
based inNottingham, UNITED KINGDOM
Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...
EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells. EarlyCDT Lung is the world’s most ...
based inSouth San Francisco, CALIFORNIA (USA)
Veracyte is a pioneering genomic diagnostics company. Our tests provide trustworthy and actionable ANSWERS that improve care throughout the patient journey. We ask the right questions and provide answers that give physicians and patients a clearer ...
Avoiding unnecessary procedures, speeding time to diagnosis and appropriate treatment. Lung cancer is the leading cancer killer worldwide, causing approximately 1.8 million deaths each year. ...
based inMenlo Park, CALIFORNIA (USA)
We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power ...
Evaluation of a New Blood Test for Detecting Multiple Types of Cancer Early. The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll ...
based inNewtown, PENNSYLVANIA (USA)
Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...
Narazaciclib (ON 123300) is a multi-kinase inhibitor targeting CDK 4/6 and additional kinases involved in tumor genesis, which the Company believes presents an innovative approach to treating advanced cancers including HR+ HER2- metastatic breast ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Dubermatinib (TP-0903) is an investigational inhibitor of AXL receptor tyrosine kinase (RTK), a protein known to be involved in acquiring resistance to chemotherapeutics, immune evasion, and developing metastatic capacity in cancer ...
based inWuhan, CHINA
Cubic Sensor and Instrument Co., Ltd. (hereinafter referred to as "Cubic") is a publicly listed company in SSE STAR Market (stock code:688665), specializing in smart gas sensors and superior gas analyzers. Set up in 2003, situated at Optics Valley ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our ...
based inWoodcliff Lake, NEW JERSEY (USA)
Eagle is a specialty pharmaceutical company working to advance safe and efficient injectable treatments for patients across oncology, critical care, and orphan diseases. At Eagle, we are committed to developing innovative drugs that result in ...
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a ...
based inGaithersburg, MARYLAND (USA)
20/20 GeneSystems Inc. develops and commercializes diagnostic tests for the early detection of cancer to improve outcomes of people at high risk for specific types of cancers. It offers blood tests for use in the United States to aid in the early ...
based inBuffalo, MINNESOTA (USA)
PenRad offers a total solution for breast imaging and Low Dose Computed Tomography (LDCT) lung screening, enhancing practice workflow. Designed for flexible and for easy integration, PenRad’s client/server SQL enterprise architecture supports all ...
Lung screening presents a number of challenges for diagnostic imaging centers with Low Dose Computed Tomography (LDCT). Patients must be screened for eligibility requirements, and participating centers are required to upload ...
based inEdgewater, NEW JERSEY (USA)
Menssana Research is the leading developer of advanced new breath tests for detection of disease. Early detection of diseases can often bring huge benefits: some cancers can be completely eradicated if they are detected early and treated promptly. ...
Every year in the U.S.A., 99,000 men and 78,000 women develop lung cancer, and only 14% of them are still alive five years later. Fortunately, early detection and treatment can reduce the number of deaths. Clinical ...
based inCambridge, UNITED KINGDOM
Owlstone Medical is developing a breathalyzer for disease. With a goal to find ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health and other conditions. Our mission is to save 100,000 lives and ...
based inPalo Alto, CALIFORNIA (USA)
BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity. To ...
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to ...
based inCoralville, IOWA (USA)
VIDA is a precision lung health company, accelerating therapies to patients through AI-powered lung intelligence. VIDA Discovery services enable more efficient respiratory clinical trials by providing more precise quantitative endpoints, AI-powered ...